

MedImmune

Specialty Care Division of AstraZeneca

LAIV Supply Update

Kathleen Coelingh, PhD Senior Director, Medical Affairs

ACIP Meeting

February 26, 2014

Seasonal Live Attenuated Influenza Vaccine (LAIV)


- Approved in US for eligible individuals 2–49 years of age
- Contains 10^{6.5-7.5} FFU* of each strain per dose
 Quadrivalent in US starting in 2013-14 season
- Contains no preservatives or adjuvants
- ◆ **Stored** at 2–8°C (refrigerator)
- Administered as nasal spray
- ♦ >75 million doses distributed since 2003



*Fluorescent focus units




Total Doses of LAIV Produced by Season




* 2009-10 doses produced includes monovalent pandemic H1N1 vaccine doses
 ‡ 2014-15 doses produced is tentative forecast number

LAIV Has Been Increasingly Administered to US Children 2-17 Years of Age*



* Based on national insurance claims data; Excludes 2009 H1N1 pandemic vaccinations. Presented by Antonova et al. at 2013 ID Week, Oct 2-6, 2013

Current and Projected LAIV Manufacturing Capacity Compared to Potential Demand



Estimates assume 50% vaccination rate of US children 2-17 years (any vaccine type).
 Manufacturing capacity projected to increase to 47 million doses for 2016-17 season.

LAIV Supply Summary


- Current and projected manufacturing capacity is sufficient for eligible US children 2-17 years
 - At current and higher future LAIV use
 - At current and higher future vaccination coverage
 - For US and ex-US demand
- Additional increases in demand can be met by further increases in manufacturing capacity

Thank You



LAIV Efficacy in First and Second Seasons of Vaccination

4 Randomized Placebo-controlled Studies, All Matched Strains Two doses in Year 1, One dose in Year 2



Study 1: Belshe et al., 1998; NEJM 338:1405-1412. Belshe et al., 2000; J Peds 136:168-175. Study 2: Vesikari et al., 2006; Pediatrics 118:2298-2312. Study 3: Bracco et al., 2009; PIDJ 28:365-371. Study 4: Tam et al., 2007; PIDJ 26:619-628